Current Neuro-Oncology

Volume 14 Number 12
31 December 2012

Home > Publications > Current Neuro-Oncology > Volume 14, Year 2012 > Number 12, 31 December

Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD.
Limited Margins Using Modern Radiotherapy Techniques Does Not Increase Marginal Failure Rate of Glioblastoma.
Am J Clin Oncol. 2012 Dec 1. 2014;37(2):177-81. doi: 10.1097/COC.0b013e318271ae03
🡥. PMID: 23211224🡥. Retrospective analysis. 🡥

Duntze J, Litré CF, Eap C, Théret E, Debreuve A, Jovenin N, Lechapt-Zalcman E, Metellus P, Colin P, Guillamo JS, Emery E, Menei P, Rousseaux P, Peruzzi P.
Implanted Carmustine Wafers Followed by Concomitant Radiochemotherapy to Treat Newly Diagnosed Malignant Gliomas: Prospective, Observational, Multicenter Study on 92 Cases.
Ann Surg Oncol. 2012 Dec 2. 2013;20(6):2065-72. doi: 10.1245/s10434-012-2764-x
🡥. PMID: 23212763🡥. Prospective study. 🡥

Leibetseder A, Ackerl M, Flechl B, Wöhrer A, Widhalm G, Dieckmann K, Kreinecker SS, Pichler J, Hainfellner J, Preusser M, Marosi C.
Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).
Neuro Oncol. 2012 Dec 7. 2013;15(1):112-21. doi: 10.1093/neuonc/nos283
🡥. PMID: 23223340🡥. Retrospective analysis. 🡥

Wagoner MP, Roopra A.
A REST derived gene signature stratifies glioblastomas into chemotherapy resistant and responsive disease.
BMC Genomics. 2012 Dec 7;13:686. doi: 10.1186/1471-2164-13-686
🡥. PMID: 23216891🡥. Laboratory investigation. 🡥

Shibui S, Narita Y, Mizusawa J, Beppu T, Ogasawara K, Sawamura Y, Kobayashi H, Nishikawa R, Mishima K, Muragaki Y, Maruyama T, Kuratsu J, Nakamura H, Kochi M, Minamida Y, Yamaki T, Kumabe T, Tominaga T, Kayama T, Sakurada K, Nagane M, Kobayashi K, Nakamura H, Ito T, Yazaki T, Sasaki H, Tanaka K, Takahashi H, Asai A, Todo T, Wakabayashi T, Takahashi J, Takano S, Fujimaki T, Sumi M, Miyakita Y, Nakazato Y, Sato A, Fukuda H, Nomura K.
Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
Cancer Chemother Pharmacol. 2012 Dec 11. 2013;71(2):511-21. doi: 10.1007/s00280-012-2041-5
🡥. PMID: 23228988🡥. Phase 2-3 trial. 🡥

Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F.
A phase II trial of oral gimatecan for recurrent glioblastoma.
J Neurooncol. 2012 Dec 12. 2013;111(3):347-53. doi: 10.1007/s11060-012-1023-0
🡥. PMID: 23232808🡥. Phase 2 trial. 🡥

Lomax AJ, Hill PA, Ashley DM.
Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
J Oncol Pharm Pract. 2012 Dec 12. 2013;19(4):365-8. doi: 10.1177/1078155212466421
🡥. PMID: 23235917🡥. Case report. 🡥

Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I.
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Neuro Oncol. 2012 Dec 14. 2013;15(2):242-50. doi: 10.1093/neuonc/nos295
🡥. PMID: 23243055🡥. Phase 2 trial. 🡥

Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, López R, Rodríguez-Serrano F, Aránega A.
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.
J Transl Med. 2012 Dec 17;10:250. doi: 10.1186/1479-5876-10-250
🡥. PMID: 23245659🡥. Retrospective analysis. 🡥

Arcella A, Biagioni F, Antonietta Oliva M, Bucci D, Frati A, Esposito V, Cantore G, Giangaspero F, Fornai F.
Rapamycin inhibits the growth of glioblastoma.
Brain Res. 2012 Dec 19. 2013;1495:37-51. doi: 10.1016/j.brainres.2012.11.044
🡥. PMID: 23261661🡥. Laboratory investigation. 🡥

Gutenberg A, Bock HC, Reifenberger G, Brück W, Giese A.
Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Acta Neurochir (Wien). 2012 Dec 20. 2013;155(3):429-35. doi: 10.1007/s00701-012-1583-y
🡥. PMID: 23254891🡥. Retrospective analysis. 🡥

Hiniker A, Hagenkord JM, Powers MP, Aghi MK, Prados MD, Perry A.
Gliosarcoma arising from an oligodendroglioma (oligosarcoma).
Clin Neuropathol. 2012 Dec 20. 2013 May-Jun;32(3):165-70. doi: 10.5414/NP300577
🡥. PMID: 23254140🡥. Case report. 🡥

Farace P, Amelio D, Ricciardi GK, Zoccatelli G, Magon S, Pizzini F, Alessandrini F, Sbarbati A, Amichetti M, Beltramello A.
Early MRI changes in glioblastoma in the period between surgery and adjuvant therapy.
J Neurooncol. 2012 Dec 22. 2013;111(2):177-85. doi: 10.1007/s11060-012-0997-y
🡥. PMID: 23264191🡥 Retrospective analysis. 🡥

Lettau M, Jedrusik P, Laible M.
Dural Metastases of a Glioblastoma.
Clin Neuroradiol. 2012 Dec 23. 2013;23(4):323-5. doi: 10.1007/s00062-012-0192-8
🡥. PMID: 23263292🡥. Case report. 🡥


Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S, Singhal S.
Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery.
Proc Natl Acad Sci U S A. 2012 Dec 27, 2013;110(5):E415-24
🡥. doi: 10.1073/pnas.1211850110🡥. PMID: 23271806🡥. Laboratory investigation. 🡥